Literature DB >> 21972433

When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data.

Lauren E Cain1, James M Robins, Emilie Lanoy, Roger Logan, Dominique Costagliola, Miguel A Hernán.   

Abstract

Dynamic treatment regimes are the type of regime most commonly used in clinical practice. For example, physicians may initiate combined antiretroviral therapy the first time an individual's recorded CD4 cell count drops below either 500 cells/mm3 or 350 cells/mm3. This paper describes an approach for using observational data to emulate randomized clinical trials that compare dynamic regimes of the form “initiate treatment within a certain time period of some time-varying covariate first crossing a particular threshold." We applied this method to data from the French Hospital database on HIV (FHDH-ANRS CO4), an observational study of HIV-infected patients, in order to compare dynamic regimes of the form "initiate treatment within m months after the recorded CD4 cell count first drops below x cells/mm3" where x takes values from 200 to 500 in increments of 10 and m takes values 0 or 3. We describe the method in the context of this example and discuss some complications that arise in emulating a randomized experiment using observational data.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21972433      PMCID: PMC3406513          DOI: 10.2202/1557-4679.1212

Source DB:  PubMed          Journal:  Int J Biostat        ISSN: 1557-4679            Impact factor:   0.968


  18 in total

1.  Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies.

Authors:  Stephen R Cole; Rui Li; Kathryn Anastos; Roger Detels; Mary Young; Joan S Chmiel; Alvaro Muñoz
Journal:  Stat Med       Date:  2004-11-15       Impact factor: 2.373

Review 2.  Comparison of dynamic treatment regimes via inverse probability weighting.

Authors:  Miguel A Hernán; Emilie Lanoy; Dominique Costagliola; James M Robins
Journal:  Basic Clin Pharmacol Toxicol       Date:  2006-03       Impact factor: 4.080

3.  Estimation and extrapolation of optimal treatment and testing strategies.

Authors:  James Robins; Liliana Orellana; Andrea Rotnitzky
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

4.  Does obesity shorten life? The importance of well-defined interventions to answer causal questions.

Authors:  M A Hernán; S L Taubman
Journal:  Int J Obes (Lond)       Date:  2008-08       Impact factor: 5.095

5.  Causal effect models for realistic individualized treatment and intention to treat rules.

Authors:  Mark J van der Laan; Maya L Petersen
Journal:  Int J Biostat       Date:  2007       Impact factor: 0.968

6.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study.

Authors:  Jonathan A C Sterne; Miguel A Hernán; Bruno Ledergerber; Kate Tilling; Rainer Weber; Pedram Sendi; Martin Rickenbach; James M Robins; Matthias Egger
Journal:  Lancet       Date:  2005 Jul 30-Aug 5       Impact factor: 79.321

7.  Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.

Authors:  D W Cameron; M Heath-Chiozzi; S Danner; C Cohen; S Kravcik; C Maurath; E Sun; D Henry; R Rode; A Potthoff; J Leonard
Journal:  Lancet       Date:  1998-02-21       Impact factor: 79.321

8.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

9.  Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán; James M Robins; Kathryn Anastos; Joan Chmiel; Roger Detels; Carolyn Ervin; Joseph Feldman; Ruth Greenblatt; Lawrence Kingsley; Shenghan Lai; Mary Young; Mardge Cohen; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

10.  Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.

Authors:  Christophe Piketty; Hana Selinger-Leneman; Sophie Grabar; Claudine Duvivier; Manuela Bonmarchand; Laurent Abramowitz; Dominique Costagliola; Murielle Mary-Krause
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

View more
  80 in total

Review 1.  Application of marginal structural models in pharmacoepidemiologic studies: a systematic review.

Authors:  Shibing Yang; Charles B Eaton; Juan Lu; Kate L Lapane
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-24       Impact factor: 2.890

2.  Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients.

Authors:  Yi Zhang; Mae Thamer; James Kaufman; Dennis Cotter; Miguel A Hernán
Journal:  Med Care       Date:  2014-03       Impact factor: 2.983

3.  Targeted Maximum Likelihood Estimation for Dynamic and Static Longitudinal Marginal Structural Working Models.

Authors:  Maya Petersen; Joshua Schwab; Susan Gruber; Nello Blaser; Michael Schomaker; Mark van der Laan
Journal:  J Causal Inference       Date:  2014-06-18

4.  Epidemiology's continuing contribution to public health: The power of "Then and Now".

Authors:  Germaine M Buck Louis; Michael S Bloom; Nicolle M Gatto; Carol R Hogue; Daniel J Westreich; Cuilin Zhang
Journal:  Am J Epidemiol       Date:  2015-03-25       Impact factor: 4.897

5.  Diagnosing Covariate Balance Across Levels of Right-Censoring Before and After Application of Inverse-Probability-of-Censoring Weights.

Authors:  John W Jackson
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

6.  Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals.

Authors:  Ellen C Caniglia; James M Robins; Lauren E Cain; Caroline Sabin; Roger Logan; Sophie Abgrall; Michael J Mugavero; Sonia Hernández-Díaz; Laurence Meyer; Remonie Seng; Daniel R Drozd; George R Seage Iii; Fabrice Bonnet; Fabien Le Marec; Richard D Moore; Peter Reiss; Ard van Sighem; William C Mathews; Inma Jarrín; Belén Alejos; Steven G Deeks; Roberto Muga; Stephen L Boswell; Elena Ferrer; Joseph J Eron; John Gill; Antonio Pacheco; Beatriz Grinsztejn; Sonia Napravnik; Sophie Jose; Andrew Phillips; Amy Justice; Janet Tate; Heiner C Bucher; Matthias Egger; Hansjakob Furrer; Jose M Miro; Jordi Casabona; Kholoud Porter; Giota Touloumi; Heidi Crane; Dominique Costagliola; Michael Saag; Miguel A Hernán
Journal:  Stat Med       Date:  2019-03-18       Impact factor: 2.373

7.  Beyond the intention-to-treat in comparative effectiveness research.

Authors:  Miguel A Hernán; Sonia Hernández-Díaz
Journal:  Clin Trials       Date:  2011-09-23       Impact factor: 2.486

8.  Comparative effectiveness of early versus conventional timing of dialysis initiation in advanced CKD.

Authors:  Deidra C Crews; Julia J Scialla; L Ebony Boulware; Sankar D Navaneethan; Joseph V Nally; Xiaobo Liu; Susana Arrigain; Jesse D Schold; Patti L Ephraim; Stacey E Jolly; Stephen M Sozio; Wieneke M Michels; Dana C Miskulin; Navdeep Tangri; Tariq Shafi; Albert W Wu; Karen Bandeen-Roche
Journal:  Am J Kidney Dis       Date:  2014-02-06       Impact factor: 8.860

9.  From exposures to population interventions: pregnancy and response to HIV therapy.

Authors:  Daniel Westreich
Journal:  Am J Epidemiol       Date:  2014-02-25       Impact factor: 4.897

10.  Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies.

Authors:  Yi Zhang; Jessica G Young; Mae Thamer; Miguel A Hernán
Journal:  Health Serv Res       Date:  2017-05-30       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.